SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Ligand (LGND) Breakout!
LGND 200.79-0.2%Nov 14 9:30 AM EST
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Sleepman who wrote (22585)6/22/1998 5:10:00 AM
From: Henry Niman  Read Replies (1) of 32384
 
Dan, Thanks for the heads up. Actually, LGND is indirectly mentioned a third time. Michael Sporn is also quoted and he did the study which showed that Panretin could prevent breast cancer and synergize with Tamoxifen. That work set the stage for the two ongoing combination trials (Panretin and Tamoxifen), as well as all of the Targretin data (Sporn was thanked in the acknowledgement section of the "Beyond Tamoxifen" paper).
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News